# Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

> **NCT05407324** · PHASE2 · RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 279 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Dazucorilant 300 mg
- **DRUG:** Dazucorilant 150 mg
- **OTHER:** Placebo
- **DRUG:** Dazucorilant

## Key facts

- **NCT ID:** NCT05407324
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-15
- **Primary completion:** 2026-09
- **Final completion:** 2027-11
- **Target enrollment:** 279 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407324, "Dazucorilant in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05407324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*